SCHEMBL23361963

SCHEMBL23361963

CC(C)(C)OC(=O)N1CCC(Nc2cccc(OCc3ccc(Cl)cn3)n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.49
CNR1 P21554 3/20 0.46
CNR2 P34972 1/20 0.46
PRMT5 O14744 1/20 0.46
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NOS2 P35228 2/20 0.43
NOS1 P29475 1/20 0.43
GPR119 Q8TDV5 3/20 0.43
IDH1 O75874 1/20 0.42
IDH2 P48735 1/20 0.42
BTK Q06187 1/20 0.42
USP30 Q70CQ3 1/20 0.42
JAK1 P23458 1/20 0.41
SYK P43405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25248223 0.85 MEN1 (0.45) PRMT5ALDH1A1MAPTGPR119
SCHEMBL29052799 0.79 CCNT1 (0.47) CCNT1GPR119IDH1USP30
SCHEMBL29052798 0.79 CCNT1 (0.47) CCNT1GPR119IDH1USP30
SCHEMBL23361817 0.79 ALDH1A1 (0.58) CCNT1CNR1CNR2PRMT5ALDH1A1
SCHEMBL23383324 0.77 IRAK4 (0.49) CCNT1
SCHEMBL29946022 0.76 NR3C1 (0.44) ALDH1A1GPR119STS
SCHEMBL22895670 0.76 USP30 (0.53) CCNT1CNR1ALDH1A1NPC1MAPT
SCHEMBL23292407 0.76 USP30 (0.53) CCNT1CNR1ALDH1A1NPC1MAPT
SCHEMBL28549787 0.76 USP30 (0.53) CCNT1CNR1ALDH1A1NPC1MAPT
SCHEMBL16136237 0.76 ALDH1A1 (0.56) CCNT1PRMT5ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002348-A1 GLP-1 Receptor Agonist and Use Thereof ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-01-05 US disclosed
US-20230002348-A1 GLP-1 Receptor Agonist and Use Thereof ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-01-05 US disclosed
EP-4059929-A1 GLP-1 RECEPTOR AGONIST AND USE THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2022-09-21 EP disclosed
CN-114728940-A GLP-1 receptor agonists and uses thereof 日东制药株式会社 2022-07-08 CN disclosed
WO-2021096284-A1 GLP-1 RECEPTOR AGONIST AND USE THEREOF 일동제약(주) 2021-05-20 WO disclosed
WO-2021096284-A1 GLP-1 RECEPTOR AGONIST AND USE THEREOF 일동제약(주) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002348-A1 GLP-1 Receptor Agonist and Use Thereof GLP1R, GIPR, GPR119 CCNT1 3823/4885CNR1 317/4885CNR2 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.